Shares of Baxter International (BAX) moved higher in the latest session after TD Cowen lifted its valuation outlook on the stock while keeping a neutral rating, drawing fresh attention to the healthcare supplier.

The TD Cowen revision comes after a strong run in Baxter International's share price, with a 90 day share price return of 44.20% and a year to date share price return of 24.97%. However, the 1 year total shareholder return has declined 14.78% and the 5 year total shareholder return has fallen 64.65%, which suggests that short term momentum has recently picked up against a weaker longer term experience for shareholders.

If this kind of rebound catches your interest, it could be a good moment to widen your watchlist and check out 40 healthcare AI stocks

Baxter International has surged in recent months after a difficult few years, which leaves a familiar fork in the road. Is this a sensible point to build exposure, or does patience for a better entry make more sense once you look at valuation?

Most Popular Narrative: 13.1% Overvalued

The most followed narrative for Baxter International puts fair value at $21.54, below the last close of $24.37, which frames the current rebound as relatively full.

Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth. The appointment of a new CEO with a track record in operational excellence is expected to accelerate transformation initiatives, refocus the organization on innovation and commercial execution, and support long-term expansion in operating margins and EPS.

Curious what sits behind that $21.54 figure for Baxter International. The narrative leans on a specific mix of revenue growth, margin repair, and a higher future earnings multiple. The exact blend matters more than any single line item.

Result: Fair Value of $21.54 (OVERVALUED)

However, Baxter International still faces execution risk if hospital IV fluid usage stays structurally lower and if margin pressures from product mix and stranded costs persist longer than expected.

Another View On Baxter International’s Valuation

The analyst narrative pegs Baxter International at $21.54 and frames the stock as overvalued on that basis. Our DCF model points the other way, with an estimated future cash flow value of $30.18, which is about 19% above the current $24.37 price. Which framework do you find more persuasive when the signals conflict?

Next Steps

If the split between risks and rewards around Baxter International feels finely balanced, now is the time to review the data and firm up your own stance with the 3 key rewards and 1 important warning sign

Looking for more ideas beyond Baxter International?

If the Baxter International story has sharpened your thinking, now is the moment to widen your opportunity set with a few focused screens that surface different types of stocks.

• Target reliable compounding potential with 8 dividend fortresses that can support a more predictable income stream alongside capital growth.
• Hunt for quality at a reasonable price using the 49 high quality undervalued stocks that filters for companies with solid fundamentals at discounted valuations.
• Dial back portfolio risk by reviewing the 83 resilient stocks with low risk scores that highlights businesses with more resilient profiles when conditions become choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.